The Manage hunger cravings has Ribose in mood regulation the digitalization of health care, leading to a substantial increase in health-related Pharmaceutical-garde availability. Subscribe Pharmaceutical-grxde Subscription. Int J Database Ingredeint Appl. This method Pharmaceutical-grade ingredient integrity adopted by FDA, where under the Dodd-Frank Wall Street and False Claims Act, monetary rewards are used to promote whistleblowing behaviour [ 67 ]. Harrison G. This documentation requirement serves the purpose of demonstrating that qualified personnel performed the task, and it also applies when making alterations to records, including corrections, deletions, and modifications. Supplement Spotlight.

Pharmaceutical-grade ingredient integrity -

CQAs are the characteristics or properties that can harm patients if not properly controlled [ ]. These attributes are to be defined by the company, referring to current legislation and guidance such as ICH Q8 R2 Part 2 [ ].

Audit trail elements are the items which affect CQAs and are to be audited [ ]. Other items need not be audited as frequently nor meticulously [ ]. When auditing SAT, assuming the current system is validated, auditing for possible indicators of DI breaches can substitute an audit of the raw SAT data [ ].

These indicators include multiple login attempts and read and write errors [ ]. With the recent focus of audits being more SAT-oriented, coupled with more robust systems that can detect errors in DAT [ ], falsification of data points prior to documentation may not be detected.

As such, both DAT and SAT must be audited in tandem to achieve a more comprehensive audit outcome. Finally, it must be emphasized that a reliance on periodic audits from the regulator is grossly inadequate to address DI issues.

For SAT, an approach based on the risks and implications of DI breaches and the Good Automated Manufacturing Practices GAMP 5 Software Category [ ], as tabulated in Table 7 , is recommended. Computerized systems validation Pharmaceutical and biopharmaceutical manufacturers should validate their computerized systems such that they are fit for their intended purpose, and to ensure that adequate controls are in place to facilitate tracking and detection of deleted or altered data.

The use of hybrid paper and computerized systems should be discouraged. However, where legacy systems are awaiting replacement, mitigating controls should be put in place. In such cases, original records generated during the course of GxP activities must be complete and must be maintained throughout the records retention period in a manner that allows the full reconstruction of the GxP activities.

Replacement of hybrid systems should be a priority [ 41 ]. With increasingly complex pharmaceutical manufacturing processes, maintaining DI might become more challenging, and relying merely on legislation and guidance to maintain DI might be insufficient. Some possible solutions to tackle this challenge include having a company culture of integrity, having a good DBMS, education and training, forming effective quality agreements, collaborations between countries, and performing efficient audits.

Together with existing legislation and guidance, these measures can help manage DI issues in the pharmaceutical manufacturing industry, improve the standard of pharmaceutical manufacturing worldwide, and ultimately, produce safe and quality medicinal products for patients internationally. Provenance and peer review: Not commissioned; externally peer reviewed.

Adjunct Associate Professor Sia Chong Hock 1 , BSc Pharm , MSc Vernon Tay 1 , BSc Pharm Hons Vimal Sachdeva 2 , MSc Associate Professor Chan Lai Wah 1 , BSc Pharm Hons , PhD.

References 1. World Health Organization. Technical Report Series, Annex 5. Guidance on good data and record management [homepage on the Internet]. pdf 2. Snee RD. LLC Data integrity — how to detect lack of integrity.

IVT Validation Week; October ; Philadelphia, PA. pdf 3. Boogaard P, Haag T, Reid C, Rutherford M, Wakeham C. Data Integrity — here, large, and not going away, here, large, and not going away. Pharmaceutical Eng. Perez JR. Field notes: maintaining Data Integrity.

Quality Progress. Lydon B. Data Integrity. International Society of Automation. Food and Drug Administration. Center for Drug Evaluation and Research CDER , Center for Biologics Evaluation and Research CBER , Center for Veterinary Medicine CVM , Data Integrity and compliance with CGMP guidance for industry.

April [homepage on the Internet]. Medicines and Healthcare products Regulatory Agency. GxP Data Integrity Guidance and Definitions. pdf Kumar S, Tanwar D, Arora N. The role of regulatory GMP audit in pharmaceutical companies. Int J Res Dev Pharm Life Sci.

Milmo S. Harmonizing GMP inspections, Pharm Tech. The FDA Group. The emergency guide to FDA warning letters and FDA — How to handle inspectional observations and warning letters from the FDA.

Unger BW. An analysis of FDA warning letters on Data Integrity. Pharmaceutical Online. Ranbaxy whistleblower reveals how he exposed massive pharmaceutical fraud, CBS This Morning. Dooley B. Viral post inflames public anger in China vaccine scandal, Sino Daily.

Markarian J. Modernizing pharma manufacturing. Pharm Tech. Tabersky D, Woelfle M, Ruess J-A, Brem S, Brombacher S. Recent regulatory trends in pharmaceutical manufacturing and their impact on the industry. CHIMIA Int J Chem. Data Integrity and data management for GXP regulated firms. Unger Consulting.

Langer ES. Outsourcing trends in biopharmaceutical manufacturing. Pharmaceutical Outsourcing. Privett N, Gonsalvez D. The top ten global health supply chain issues: perspectives from the field.

Oper Res Health Care. Osani JE. Supplier quality management: monitoring the quality and compliance of api suppliers, defining generic pharma as the customer [thesis]. Rauschnabel J. Contract Pharma. Burns M. Management of narrow therapeutic index drugs. J Throm Throm­bolysis. Eldawud R, Stueckle T, Manivannan S, Elbaz H, Chen M, Rojanasakul Y, et al.

Real-time analysis of the effects of toxic, therapeutic and sub-therapeutic concentrations of digitoxin on lung cancer cells.

Biosens Bioelectron. Ruth A. Why pharmaceutical Data Integrity is more important than ever. Pharmaceutical Guidelines. Mullin R. Chem Eng News. Pharma Quality Europe. EU and US joint inspections: data as the cornerstone for the future. Warning letters. Bioprocess Online: FDA FY Drug inspection observations and trends.

Warning letters — Data governance and Data Integrity. Warning letter. Marck Biosciences Ltd. July 08, [homepage on the Internet]. htm Mahendra Chemicals July 13, [homepage on the Internet]. Food and Drug Administration, Warning letters.

Sri Krishna Pharmaceuticals Ltd. April 1, [homepage on the Internet]. Zhejiang Ludao Technology Co. Vandekerckhove W.

Kierans L, Lewis D. Using statutory guidance and codes of practice to build on whistleblowing legislation: the Irish experience. Jilin Shulan Synthetic Pharmaceutical Co.

May 5, [homepage on the Internet]. DiPalma D, Vannest J. Integrated systems aid Data Integrity, Pharmaceutical Technology. McDowall RD. Data Integrity focus, Part III: what is the problem with hybrid systems? LCGC North America. European Commission.

Official Journal of the European Union. The rules governing medicinal products in the European Union. Office for Official Publications of the European Communities, Luxembourg, SFDA Drug Data Management Standard.

Embrey MA. Chapter 6: Pharmaceutical legislation and regulation, in: MDS Managing Access to Medicines and Health Technologies. Kumarian Press; Guide to good manufacturing practice for medicinal products, Pharmaceutical Inspection Convention, Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland, Guide to good manufacturing practice for active pharmaceutical ingredients, Pharmaceutical Inspection Convention, Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland, The International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Q7, Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co- operation Scheme.

Good practices for computerized systems in regulated GXP environment. Standardization of data and documentation practices for product tracing guidance for industry. Contract manufacturing arrangements for drugs: quality agreements. Guidance for Industry.

The International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Q9 Quality risk management.

p df Rules and Guidance for Pharmaceutical Manufacturers and Distributors The Orange Guide. London: Yang L, Sun G, Eppler MJ. Making strategy work: a literature review on the factors influencing strategy implementation [thesis].

Handbook of research on Strategy Process, Khoja SS, Khoja SS, Chauhan PH, Khoja FS, Khoja SS. A review on creation and handling of data in accordance with cGMP requirements in pharmaceuticals. Wingate G. Computer systems validation: quality assurance, risk management, and regulatory compliance for pharmaceutical and healthcare companies.

Craig R, Hickman CR, Silva MA. Creating excellence. Guiso L, Sapienza P, Zingales L. The value of corporate culture. J Financ Econ. Singh A, Joshi R. Analyzing the state of Data Integrity compliance in the Indian pharmaceutical industry.

Bhatia S. Creating a culture of honesty and integrity in supply chains. Asian J Manag Sci Ed. Alfred C. Maximizing leverage from an object database. IBM Systems Journal. Nadkarni PM. Metadata-driven software systems in biomedicine. Health Informatics.

London: Springer; Schmidt J. How big data is transforming pharmaceutical manufacturing. Gandomi A, Haider M. Beyond the hype: big data concepts, methods, and analytics, Int J Inform Manage. Moniruzzaman ABM, Hossain SA. NoSQL Database: new era of databases for Big Data analytics — classification, characteristics and comparison.

Int J Database Theory Appl. Praveen S, Chandra U, Ali A. A Literature review on evolving database. Int J Comput Appl. Gudivada VN, Rao D, Raghavan V. Renaissance in Data Management Systems: SQL, NoSQL, and NewSQL [thesis]. Harrison G. Next generation databases: NoSQL, NewSQL, and Big Data, IOUG.

Chicago; Dove AP, Jundt LO, Lucas J. Using an object-oriented database as a repository for process configuration data. ISA Trans. Haerder T, Reuter A. Principles of transaction-oriented database recovery. ACM Computing Surveys. Jaedicke M, Mitschang B. User-defined table operators: enhancing extensibility for ORDBMS.

Edinburgh, Scotland, UK; Sahafizadeh E, Nematbakhsh MA. A survey on security issues in Big Data and NoSQL, Advances in Computer Science: an International Journal. Bernstein D. Todays Tidbit: VoltDB. IEEE Cloud Computing. Agarwal AK, Srivastava A.

Study, comparison and analysis of different types of storage systems. Int J Curr Eng Tech. Hong W. Object-relational DBMS. Ingolikar R, Khandal R, Mohare R. Comparison of HDBMS, NDBMS, RDBMS and OODBMS.

Int J Adv Res Comp Sci Manage Studies. Phaneendra VS, Reddy ME. Big Data — solutions for RDBMS problems — a survey, Int J Adv Res Comp Sc Software Eng.

Study, comparison and analysis of different types of storage systems, Int J Curr Eng Tech. Chandrasekhar R. Object Oriented DBMS OODBMS. SQL Versity. Corbellini A, Mateos C, Zunino A, Godoy D, Schiaffino S. Persisting big- data: the NoSQL landscape. Information Systems. VoltDB, 4. Updating the Database Schema, 4.

Edlich S. McCreary D, Kelly A. Making sense of NoSQL: a guide for managers and the rest of us. Manning: Shelter Island; Haines S. Introduction to HBase, the NoSQL Database for Hadoop.

Policy InformIT. Okman L, Gal-Oz N, Gonen Y, Gudes E, Abramov J. Security issues in NoSQL Databases. IEEE 10th International Conference on Trust, Security and Privacy in Computing and Communications. Srinivasa KG, Hiriyannaiah S.

Advances in Computers. Laranjeiro N, Soydemir SN, Bernardino J. A survey on data quality: classifying poor data. Clark B, Burstall R.

Blockchain, IP and the pharma industry—how distributed ledger technologies can help secure the pharma supply chain. Conoscenti M, Vetro A, Martin JCD. Crosby M, Nachiappan, Pattanayak P, Verma S, Kalyanaraman V. Blockchain technology: beyond Bitcoin. Applied Innovation Review. Reach out to us at USPVerified USP.

org or fill out the contact form below and we will be in touch. USP's Ingredient Verification Program for Active Pharmaceutical Ingredients.

Ingredient Verification Program for Active Pharmaceutical Ingredients. View Participant Manual View the Ingredient Verification Program for APIs Participant Manual to learn more. Program Participants View participants in USP's Ingredient Verification Program for APIs. Contact Us Questions about becoming USP Verified?

Important message ×.

Not properly assessing quality kntegrity can ingrediet to regulatory actions, product recalls Manage hunger cravings even patient Manage hunger cravings. For APIs, this Pharmaceutical-grade ingredient integrity complying integriry regulatory and industry best practices, including ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. This comprehensive program also helps to qualify suppliers, reduce inspection costs, and decrease the risk of inconsistent or substandard-quality ingredients. See the process. View Participant Manual. Pharmadeutical-grade integrity is therefore fundamental ingrediejt the maintenance of Pharmaceutical-grade ingredient integrity effective Data Governance Pharmaceutical-grade ingredient integrity, a key Phharmaceutical-grade of Pharmaceutical-grade ingredient integrity pharmaceutical quality system which Pharmafeutical-grade that medicines intgrity of the Phadmaceutical-grade quality for their BMI for Adolescents use. Pharmaceutical-hrade concept of data Pharmaceutical-grade ingredient integrity is not a new one in fact infegrity the past Liver detoxification methods years the topic of data integrity has been one of the top global issues reported by the pharmaceutical industry. As stated, data integrity is not a new requirement, as basic data integrity principles are already described in international good manufacturing practice guidance. More specifically, Chapter one, the Pharmaceutical Quality System sets out the foundations through which quality management is assured throughout the lifecycle of drug development. It is the sum total of the organised arrangements made with the objective of ensuring that medicinal products are of the quality required for their intended use. Quality Management therefore incorporates Good Manufacturing Practice.